{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:35:16Z","timestamp":1762551316782,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015098","name":"Seoul National University Seoul Metropolitan Government Boramae Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102379","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T19:20:41Z","timestamp":1747768841000},"page":"102379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidences of Secondary Malignancies After Androgen Deprivation Therapy for Prostate Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Junghoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwancheol","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-7053","authenticated-orcid":false,"given":"Sangjun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2025.102379_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca Cancer J Clin"},{"issue":"2","key":"10.1016\/j.clgc.2025.102379_bib0002","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4143\/crt.2023.447","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020","volume":"55","author":"Kang","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clgc.2025.102379_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102379_bib0004","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.clgc.2025.102379_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102379_bib0006","doi-asserted-by":"crossref","DOI":"10.5534\/wjmh.220200","article-title":"Systemic therapies for metastatic castration-resistant prostate cancer: an updated review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J Men's Health"},{"issue":"2","key":"10.1016\/j.clgc.2025.102379_bib0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.clgc.2025.102379_bib0008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.eururo.2007.07.002","article-title":"Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk?","volume":"52","author":"Bostrom","year":"2007","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.clgc.2025.102379_bib0009","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clgc.2025.102379_bib0010","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1038\/s41598-022-13361-4","article-title":"Hypothalamic connectivities predict individual differences in ADT-elicited changes in working memory and quality of life in prostate cancer patients","volume":"12","author":"Chaudhary","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.clgc.2025.102379_bib0011","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1158\/1055-9965.EPI-12-1137","article-title":"Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies","volume":"22","author":"Wallner","year":"2013","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"10.1016\/j.clgc.2025.102379_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5306\/wjco.v7.i1.54","article-title":"Historical review of the causes of cancer","volume":"7","author":"Blackadar","year":"2016","journal-title":"World J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102379_bib0013","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"10.1016\/j.clgc.2025.102379_bib0014","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/JCO.2009.27.4290","article-title":"Influence of sex hormones on cancer progression","volume":"28","author":"Folkerd","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6809","key":"10.1016\/j.clgc.2025.102379_bib0015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/35041694","article-title":"The age of cancer","volume":"408","author":"DePinho","year":"2000","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.clgc.2025.102379_bib0016","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: a systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clgc.2025.102379_bib0017","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clgc.2025.102379_bib0018","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clgc.2025.102379_bib0019","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ijc.33555","article-title":"Prospective analyses of testosterone and sex hormone-binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank","volume":"149","author":"Watts","year":"2021","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102379_bib0020","first-page":"790","article-title":"Elevated serum testosterone levels and risk of hepatocellular carcinoma","volume":"53","author":"Yu","year":"1993","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.clgc.2025.102379_bib0021","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/jgh.15079","article-title":"Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus","volume":"35","author":"Yip","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"6D","key":"10.1016\/j.clgc.2025.102379_bib0022","first-page":"4293","article-title":"Prevalence of Klinefelter's syndrome in male breast cancer patients","volume":"17","author":"Hultborn","year":"1997","journal-title":"Anticancer Res"},{"issue":"18","key":"10.1016\/j.clgc.2025.102379_bib0023","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.2014.59.1602","article-title":"Prediagnostic sex steroid hormones in relation to male breast cancer risk","volume":"33","author":"Brinton","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102379_bib0024","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1245\/s10434-014-4066-y","article-title":"Coupling of prostate and thyroid cancer diagnoses in the United States","volume":"22","author":"Tomaszewski","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102379_bib0025","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1158\/1055-9965.EPI-20-0246","article-title":"Association of sex hormones with risk of cancers of the pancreas, kidney, and brain in the UK biobank cohort study","volume":"29","author":"Peila","year":"2020","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:31:17Z","timestamp":1762551077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000795"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102379","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidences of Secondary Malignancies After Androgen Deprivation Therapy for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102379"}}